CBO Legislative Scores Will Account For Medicare Rx’s Reductions In Other Medical Costs
This article was originally published in The Pink Sheet Daily
In a policy change, the Congressional Budget Office, which estimates the impact of legislation on federal spending, will account for pharmaceuticals’ effect on overall medical spending in Medicare for bills that directly affect drug use.
You may also be interested in...
Reimbursement Briefs: Medicaid Savings, Kcentra Payment, Formulary Discrimination Concerns
Cost reductions in Medicaid associated with increased drug use; Medicare add-on payments for Kcentra extended; patient groups seek formulary non-discrimination provisions in HHS rule.
The Sovaldi Anniversary? Burgess Wants Part D Milestone To Change How Gov’t Values Rx Spending
Congressional budget projections should use longer time horizons, Vice-Chair of House Energy and Commerce Health Subcommittee argues; meanwhile former FDA Commissioner suggests costly drugs could be paid for on a mortgage model.
Medication Therapy Management To Expand In Part D Under CMS Rule
CMS expects the proposed changes to medication therapy management will make 55% of Medicare beneficiaries eligible for MTM services, which CMS says has been shown to improve drug therapy outcomes and reduce health care costs.